ArticleThe Prostate2021

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.

Alexandra O Sokolova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.